Harnessing the Utility of Ex Vivo Patient Prostate Tissue Slice Cultures

Lillian M. Perez1,2 and Larisa Nonn1,2*

1 University of Illinois at Chicago Pathology Department, Chicago, IL, United States, 2 University of Illinois Cancer Center, Chicago, IL, United States

Patient-derived prostate tissue explant cultures are powerful research tools that offer the potential for personalized medicine. These cultures preserve the local microenvironment of the surrounding stroma but are not without limitations and challenges. There are several methods and processing techniques to culture tissue ex vivo, that include explant tissue chunks and precision-cut tissue slices. Precision-cut tissue slices provide a consistent distribution of nutrients and gases to the explant. Herein we summarize the prostate tissue slice method, its limitations and discuss the utility of this model, to investigate prostate biology and therapeutic treatment responses.

Keywords: prostate, ex vivo culture, precision medicine, prostate cancer, androgens

INTRODUCTION

Ex vivo tissue culture retains the local microenvironment and is potentially a powerful tool to examine prostate responses to treatment and/or genetic manipulation. This technique is particularly relevant to prostate, which contains several cell types including glandular epithelium, fibromuscular stroma, neuroendocrine cells, and immune cells. The crosstalk between these cell types may influence experimental responses between patients. Several methods for ex vivo prostate tissue culture have been reported, which have some similarities, but there is no established gold standard method. Briefly, prostate tissue, benign or cancer, is cultured in media within a culture vessel over the course of 2-5 days. The patient-derived explant (PDE) model typically refers to prostate tissue that is chopped, minced, or sliced with surgical tools whereas tissue slice culture (TS) utilizes a precision slicing method to cut slices into an exact thickness. These methods are also useful for ex vivo patient-derived xenografts (PDXs) from mice. This review focuses on the prostate TS method, utilization, challenges and opportunities.

EX VIVO RADICAL PROSTATECTOMY TISSUES CULTURED AS PRECISION CUT SLICES

Precision cut slices from fresh tissues enable consistent diffusion of gases across the tissue and rely on capillary action to bring culture medium into the tissues. Slices were initially developed using liver and kidney for use in pharmacology metabolism studies (1). Parrish et al. were the first to extend this method to other tissues, including prostate (2). The ex vivo culture of prostate TSs was further refined to preserve the secretory epithelium and reduce basal cell hyperplasia (3).
Androgen responsiveness is essential for any ex vivo model and the Peehl Lab showed that TS respond to androgens and androgen ablation both ex vivo and when grafted under the renal capsule of mice (3, 4).

TS relies on precise sectioning of a core of fresh radical prostatectomy tissue using a specialized tissue slicing instrument. The uniform thickness of the slices enables even nutrient and oxygen diffusion through the tissue to avoid necrosis (3). Diseases of the prostate, such as cancer, are often multi-focal and challenging to identify on gross specimens, thus it is essential to collect slices for histological examination. Culture length is variable and has been reported between one and five days, dependent on endpoints.

TISSUE SLICE CULTURE METHOD

Patient radical prostatectomy specimens or PDXs (5) have been used for prostate TS cultures (Figure 1). The detailed method has been reported by others (2, 4, 6, 7). Briefly, a 5 or 10 mm core of fresh tissue is stabilized in agar and mounted in a precision slicer, generating ~300 µm slices, which are quickly placed into culture. The majority of studies utilize titanium mesh inserts to mount slices within 6-well tissue culture plates (3, 6–12). The TS on a titanium mesh rotates on an angle to dip the TS in and out of media, driving capillary action for equivalent distribution of media and exposure to gases. However, earlier tissue cultures have utilized titanium mesh within scintillation vials (2).

Optimization of primary culture medium can be challenging and TS cultures have been tested in different mediums including KSFM, M199, MCD105, and PFMR, with additives of supplements, serum, and androgens. One of the earliest studies used KSFM on titanium mesh within scintillation vials and varied supplementation with bovine pituitary extract, EGF, DHT, and FBS (10%) (2). They concluded that DHT promotes tissue slice viability, as the medium containing DHT prevented the loss of luminal epithelial cells, and that media containing 10% FBS promotes hyper-proliferation of basal cells. This proliferation of basal cells was also observed by Maund et al., who found low levels of androgen resulted in the basal hyper-proliferation (3). Maund et al. systematically tested many conditions for TS cultures. The first condition contained a mixture of KSFM and M199 [the 1:1 ratio as reported by (7)] with 1 nM DHT and resulted in luminal cell degeneration and basal cell hyperplasia. The second media contained PFMR-4A with 10 nM R1881 and resulted in less cell loss and viability for up to two days, after-which tissue slices exhibited luminal cell degeneration and basal cell hyperplasia. The third media contained PFMR-4A with 50 nM R1881 and resulted in the most cell viability at two days, with histology, proliferation, and apoptosis that was most similar to day zero TS. In summary, assessment of viability, toxicity, proliferation, and apoptosis resulted with the media composition containing PFMR-4A and 50 nM R1881 being optimal for TS culture media and concentration of testosterone (3). However, PFMR-4A is not commercially available and others have found success using PrEGM supplemented with 50 nM R1881 (12) or serum-free aDMEM/F12 K medium with R1881 (13).

TS from patient derived xenograft models (PDX-TS), has been used in several studies. Zhang et al. did a systematic analysis on PDX-TS culture method and the effects of media composition (13). They used 3 PDX-TS and found that rocking on a cell strainer (very similar to titanium grids rotating) in serum-free aDMEM/F12 K medium with R1881 was optimal to preserve proliferation and prevent apoptosis. Proof of concept studies in PDX-TS have developed a method to examine many tissues at once in 96-well format by a method they call micro-dissected tissue (MDT) (14, 15). MDT are 500 µm in diameter, compared to normal TS which are 3-5 mm, thus MDT permits more precise tissue acquisition and potentially many more experimental endpoints. Dorrigiv et al. optimized this by using cell line xenografts as the tissue source (15). They also developed a method to create an FFPE microarray from the MDT

![FIGURE 1](image-url) | Tissue slice culture workflow and preclinical endpoints. Precision cut tissue slices (TS) derived from radical prostatectomy (RP) or a patient-derived xenograft (PDX) incubate on titanium mesh grids at a 45° angle within a rotating tissue culture plate.
(MDTMA) (14). The small MDT appeared to be free of the challenges with larger tissue pieces and preserved cell morphology, viability, and proliferation throughout 15 days of culture.

INVESTIGATION OF PROSTATE BIOLOGICAL RESPONSES USING TISSUE SLICE CULTURES

TS cultures have been utilized to target key developmental signaling pathways and validate prior findings from in vitro studies in human prostate. TS retain expression of the hormone receptors and are shown to be responsive to the hormones vitamin D (12, 16) and androgens (2, 3, 7, 9, 13, 16, 17). McCray et al. analyzed TSs treated with 25-hydroxyvitamin D and analyzed epithelial and stromal gene expression via spatial transcriptomics (12). Among a panel of genes, the Wnt pathway and DKK3 were identified as downregulated by 25-hydroxvitamin D. In another study, TS responded to both 25-hydroxvitamin D and testosterone in regulation of target genes (16). The TS also retained expression of the endocytic membrane receptor, megalin, which imports hormones into the cells (16). Importantly, in both vitamin D studies, the TS data corroborated evidence from patient-derived organoids and relationships in patient specimens, demonstrating consistency and reproducibility between models to investigate developmental pathways ex vivo.

Several studies have utilized TS cultures to investigate DNA damage responses. DNA damage response of benign radical prostatectomy-derived TS was monitored following ionizing radiation (IR) (6). They found that IR did not elicit Tyr (15) and p53 responses in TS and they suggest that absence of these DNA damage response pathways may contribute to carcinogenesis (6).

TS AND BIOMARKER DISCOVERY

TS from prostate cancer (PCa) are suited for biomarker discovery since the amount of tissue of each pathology can be controlled; matched benign/PCa tissues are available from each patient, and specimens from multiple patients can be used to account for inter-patient heterogeneity. Spichiarich et al. identified glycoproteins, specifically sialylated glycans, associated with PCa using bio-orthogonal labeling (10). They used paired benign and PCa TS from eight different patients and identified 21 proteins unique to all PCa samples and undetected in the benign tissue, including VDAC1 and the sialoglycoprotein, legumain. The unique metabolic state of PCa compared to benign tissue is preserved in TS and a source for biomarkers. The Kurhanewicz group used intracellular labeling of $^{[3,13]}$C lactate as a PCa biomarker (8). They further examined lactate by TS of various Gleason Grade and showed that high-grade PCa (N=4) has higher lactate than low grade (N=11) or benign tissue (N=15) (11).

THERAPEUTIC RESPONSES IN EX VIVO PDE AND TS

Research advancements in anti-androgen therapies, alternative therapeutics for CRPC models, and other experimental therapeutics have been made with ex vivo TS or PDEs (Table 1). PDE cultures of tissue chunks have been used more frequently than TS for these studies. Although there are limited reports that use TS to measure treatment outcomes, these reports have demonstrated responses that may inform treatments in the clinic. PDEs are described as the ex vivo culture of prostate tissue as small pieces on sponges with conditions that promote or maintain tumor microenvironment and tissue architecture. Ex vivo PCa tumor cultures have demonstrated the tumor microenvironment remains intact using established methods (21). Both low and high tumor grades (Gleason 3-5) have been cultured successfully and remain viable for up to five days (3, 8, 10, 11). The methodology for PDE cultures and the promise of their preclinical utility has been previously reviewed by others (20, 28, 29) and is only briefly discussed here.

TSs and PDEs are highly responsive to androgens and have been used to examine several anti-androgen therapies. Zhao et al. revealed that the castration response of TS grafted into mice mimicked the expression of proteins in prostate specimens from patients with androgen deprivation therapies (9). The patient heterogeneity of anti-proliferation responses to bicalutamide and enzalutamide was demonstrated in PDE (17, 18). Butler et al. further showed tumor areas resistant to enzalutamide also had aberrations in their lipid profiles (18), which lead to discovery of ELOVL5, a fatty acid elongase, as a new metabolic target of androgens (24). The potential to predict patient response to combination therapy with enzalutamide and docetaxel was shown in PDE, reflecting individual treatment outcomes observed in the clinic (21). Shafi et al. also identified heterogeneous responses to experimental therapeutics, including veliparib, palbociclib, and NU7441 (21), emphasizing that patient-specific responses may be tested in PDEs. The antiandrogen therapy, apalutamide, was shown to radiosensitize PDX-TS PCa demonstrating a possible therapeutic treatment for AR-dependent PCa (19). Explants are also useful for studying resident immune cells and PDEs were recently used to show an increase in CD163+/CD68+ macrophages after enzalutamide (23).

PDEs from PDXs have been used to test therapeutics. Galileilactalone, a STAT3 inhibitor, reduced AR activity in PDEs of thin tissue pieces (cut by a razor blade) (27). Bray et al. showed in 5 human prostatectomy-derived tumors that combination treatment with BCL-2 inhibitor, ABT-737, and cisplatin yielded a synergistic therapeutic response more than either treatment alone using ex vivo PCa TS (200 µm) (25). PDEs from PDX of CRPC demonstrated sensitivity of CRPC to BRET inhibitors (22), and PARP inhibitors (26). Zhang et al. used PDXs from 3 patients for TS cultures and observed the expected
responses to enzalutamide and olaparib, based on the AR expression and BRCA2 mutations, respectively (13).

**LIMITATIONS AND CHALLENGES OF PROSTATE TS AND EX VIVO CULTURES**

There are challenges that are common between all ex vivo culture methods and those unique to TS. The primary challenge to ex vivo cultures for TS (or PDEs) is rapid accessibility to fresh surgical specimens. This requires close collaboration and cooperation between research and clinical staff as well as pre-surgical consent of the patient to utilize excess tissue not needed for diagnosis. The size of the specimen further limits the amount of TS or PDE that can be made from it. These challenges contribute to the rarity of ex vivo CRPC cultures and underscore the importance of PDX-CRPC. To date, neuroendocrine prostate cancer (NEPC) has yet to be cultured for TS (or PDEs) is rapid accessibility to fresh surgical specimens. This requires close collaboration and cooperation between research and clinical staff as well as pre-surgical consent of the patient to utilize excess tissue not needed for diagnosis. The size of the specimen further limits the amount of TS or PDE that can be made from it. These challenges contribute to the rarity of ex vivo CRPC cultures and underscore the importance of PDX-CRPC. To date, neuroendocrine prostate cancer (NEPC) has yet to be reported for TS studies, likely owing to limited access. Identification of cancer areas on gross radical prostatectomy specimens is a challenge. Furthermore, fresh tissue pieces are never one cell type. Benign areas will contain varied amounts of glandular epithelium and stroma. PCA often presents multi-focal lesions that are not fully encapsulated in a sample. Thus, samples for ex vivo culture may contain mixed pathologies that will bias endpoints that homogenize the entire piece of tissue. The TS method preserves histological features and allows for spatial examination of endpoints such as immunohistochemistry, in situ hybridization, ISH or spatial transcriptomics. The method of MDT (described above) (14) and pathology guided micropunching (PGM) (30) sample smaller areas (260-500 µM), reducing heterogeneity of the specimens, but also provide limited tissue for endpoint analyses. The relatively short length of culture for androgen adaptation studies is a limitation to both PDEs and TS. However, several studies grafted TS under in vivo conditions, rather than in vitro culture, and were able to predict androgen sensitivity (4, 9). Finally, while TS are optimal for assessing therapeutic responses, overexpression and knockdown tools needed for mechanistic studies need to be carefully optimized to penetrate into explant tissue cultures. This includes delivery of siRNAs, as reported in localized PCa PDE cultures by Tieu et al. (31).

TS have several additional limitations. The main one is that specialized equipment is required to prepare and culture the precision slices. Secondly, as PCA tumors are small, the pathology of the specimen often drifts through the slices, requiring additional collection of slices for pathology if the endpoint of the specimen often drifts through the slices, requiring additional collection of slices for pathology if the endpoint

**OPPORTUNITIES FOR PROSTATE TS EX VIVO CULTURE**

Despite the challenges, TS cultures provide spatial examination of inter and intra-patient heterogeneity not possible by other

---

**TABLE 1** | Therapeutics tested in ex vivo prostate cultures.

| Target       | Therapeutic                                                                 | Ex Vivo Model             | Reference                  |
|--------------|------------------------------------------------------------------------------|---------------------------|----------------------------|
| ACC1/2       | PF-05175157 (10 µM, 25 µM, 50 µM)                                           | PDE                       | Butler et al., 2021 (18)   |
| AR           | Apalutamide (1 µM) + EBRT (2Gy)                                             | PDX (TS, 300 µm)          | Zhang et al., 2019a (19)   |
|              | Bicalutamide (10 µM)                                                        | PDE                       | Centenera et al., 2013 (20) |
|              | Castration                                                                  | TS grafts, 300 µm         | Zhao et al., 2013 (9)       |
|              | Enzalutamide (1 µM)                                                         | PDE                       | Shafi et al., 2018 (21)     |
|              | Enzalutamide (1 µM)                                                         | PDX (TS, 300 µm)          | Zhang et al., 2019b (13)    |
|              | Enzalutamide (10 µM)                                                        | PDE                       | Shafi et al., 2018 (21)     |
|              | Enzalutamide (10 µM, 50 µM)                                                 | PDE                       | Butler et al., 2021 (18)    |
|              | Enzalutamide (10 µM)                                                        | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
|              | Enzalutamide (10 µM)                                                        | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
|              | Enzalutamide (10 µM)                                                        | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
|              | Enzalutamide (10 µM)                                                        | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
|              | Enzalutamide (10 µM)                                                        | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
|              | Galactonitrone (10 µM)                                                      | PDE                       | Shafi et al., 2018 (21)     |
|              | Caspaplatin + ABT-737 (10 µM)                                                | PDE                       | Centenera et al., 2013 (20) |
|              | BRET iBET151 (1 µM) and JQ1 (1 µM)                                           | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
|              | Palbociclib (1 µM)                                                          | PDE                       | Shafi et al., 2018 (21)     |
|              | Ribociclib (1 µM)                                                           | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
|              | NU7441 (1 µM)                                                               | PDE                       | Shafi et al., 2018 (21)     |
|              | NVP-AUY922 (100-1000 nM)                                                    | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
| HSP90        | NVP-HSP990 (100-1000 nM)                                                    | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
|              | CX-6258 (5 µM)                                                              | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
| pan-PIM      | ABT8888 (2.5 µM)                                                            | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |
| PARP         | Olaparib (10 µM)                                                            | PDX (TS, 300 µm)          | Zhang et al., 2019a (19)    |
|              | Veliparib (2.5 µM)                                                          | PDX (TS, 300 µm)          | Zhang et al., 2019a (19)    |
|              | CRPC-PDX (PDE)                                                              | PDE                       | Shafi et al., 2018 (21)     |
| RNA polymerase I | CRPC-PDX (PDE)                  | PDE                       | Shafi et al., 2018 (21)     |
| STAT3        | CX-5461 (1 µM)                                                              | CRPC-PDX (PDE)            | Lawrence et al., 2018 (22)  |

**TS, tissue slice culture; EBRT, external beam radiation therapy; PDX, patient-derived xenograft; PDE, patient-derived explant; CRPC, castration resistance prostate cancer.**
methods. The rapid advancement and increased resolution of spatial transcriptomic methods (32, 33) offers the ability to compare transcriptomic differences (RNaseq) between areas of the tissue and between patients. Co-detection by indexing (CODEX) tissue imaging with DNA-barcode antibodies has the potential to examine up to 60 markers in one sample (34), which would greatly expand the data available from a TS experiment. Localized prostate tumors are often under hypoxia and Figiel at al recently showed that localized PCA TS respond to hypoxic culture conditions (35), which support use of TS in therapeutic response studies.

In summary, although ex vivo culture of prostate TS was first described two decades ago, it remains an emerging model that holds promise for both research questions and for precision medicine. TS are primed and amenable to recent technologic breakthroughs in single cell sequencing and spatial data collection.

REFERENCES

1. Parrish AR, Gandolfi AJ, Brendel K. Precision-Cut Tissue Slices: Applications in Pharmacology and Toxicology. Life Sci (1995) 57:1887–901. doi: 10.1016/0024-3205(95)02176-j
2. Parrish AR, Sallam K, Nyman DW, Orozco J, Cress AE, Dalkin BL, et al. Culturing Precision-Cut Human Prostate Slices as an In Vitro Model of Prostate Pathobiology. Cell Biol Toxicol (2002) 18:205–19. doi: 10.1023/a:1015567805460
3. Maund SL, Nolley R, Peehl DM. Optimization and Comprehensive Characterization of a Faithful Tissue Culture Model of the Benign and Malignant Human Prostate. Lab Invest (2014) 94:208–21. doi: 10.1038/labinvest.2013.141
4. Zhao H, Nolley R, Chen Z, Peehl DM. Tissue Slice Grafts: An In Vivo Model of Human Prostate Androgen Signaling. Am J Pathol (2010) 177:229–39. doi: 10.2353/ajpath.2010.090821
5. Kocher S, Beyer B, Lange T, Nordquist L, Volquardsen J, Burdak-Rothkamm S, et al. A Functional Ex Vivo Assay to Detect PARP1-ER Repair and Radioresistance by PARP-Inhibitor in Prostate Cancer. Int J Cancer (2019) 144:1685–96. doi: 10.1002/ijc.32018
6. Kivilharju-af Hallstrom TM, Jaamaa S, Monkkonen M, Peltonen K, Andersson LC, Medema RH, et al. Human Prostate Epithelium Lacks WtE1A-Mediated DNA Damage-Induced Checkpoint Enforcement. Proc Natl Acad Sci USA (2007) 104:7211–6. doi: 10.1073/pnas.0609299104
7. Blauer M, Tammela TL, Ylilommi T. A Novel Tissue-Slice Culture Model for non-Malignant Human Prostate. Cell Tissue Res (2008) 332:489–98. doi: 10.1007/s00441-008-0602-z
8. Keshari KR, Srizam R, Van Criekinge M, Wilson DM, Wang ZL, Vigneron DR, et al. Metabolic Reprogramming and Validation of Hyperpolarized 13C Lactate as a Prostate Cancer Biomarker Using a Human Prostate Tissue Slice Culture Bioreactor. Prostate (2013) 73:1171–81. doi: 10.1002/pros.22665
9. Zhao H, Thong A, Nolley R, Reese SW, Santos J, Ingels A, et al. Patient-Derived Tissue Slice Grafts Accurately Depict Response of High-Risk Primary Prostate Cancer to Androgen Deprivation Therapy. J Transl Med (2013) 11:199. doi: 10.1186/1479-5876-11-199
10. Spicariar DR, Nolley R, Maund SL, Purcell SC, Herschel J, Iavaroni AT, et al. Bioorthogonal Labeling of Human Prostate Tissue Slice Cultures for Glycoproteomics. Angew Chem Int Ed Engl (2017) 56:8992–7. doi: 10.1002/anie.201701424
11. Srizam R, Van Criekinge M, DeLos Santos J, Ahamed F, Qin H, Nolley R, et al. Elevated Tumor Lactate and Eflux in High-Grade Prostate Cancer Demonstrated by Hyperpolarized (13)C Magnetic Resonance Spectroscopy of Prostate Tissue Slice Cultures. Cancers (Basel) (2020) 12. doi: 10.3390/cancers12030537
12. McClay T, Pacheco JV, Loitz CC, Garcia J, Baumann B, Schlicht MI, et al. Vitamin D Sufficiency Enhances Differentiation of Patient-Derived Prostate Epithelial Organoids. Science (2021) 24:101974. doi: 10.1126/sciadv.202101974
13. Zhang W, van Weerden WM, de Ridder CMA, Erkens-Schulze S, Schonfeld F, Meijer TG, et al. Ex Vivo Treatment of Prostate Tumor Tissue Recapitulates In Vivo Therapy Response. Prostate (2019) 79:390–402. doi: 10.1002/pros.23745
14. Simeone K, Guay-Lord R, Lateef MA, Peant B, Kendall-Dupont J, Orimoto AM, et al. Paraflin-Embedding Lithography and Micro-Dissected Tissue Micro-Arrays: Tools for Biological and Pharmacological Analysis of Ex Vivo Solid Tumors. Lab Chip (2019) 19:693–705. doi: 10.1039/c8lc00982a
15. Dorrigiv D, Simeone K, Communual L, Kendall-Dupont J, St-Georges-Robillard A, Peant B, et al. Microdissected Tissue vs Tissue Slices-a Comparative Study of Tumor Explant Models Cultured On-Chip and Off-Chip. Cancers (Basel) (2013) 11. doi: 10.3390/cancers1316208
16. Garcia J, Krieger KD, Loitz C, Perez L, Richards ZA, Helou Y, et al. Vitamin D Deficiency Increases Prostatic Megalin Expression and Glibolin-Bound Testosterone Import, Increasing Prostatic Androgens in African American Men. bioRxiv (2021) 2021:466576. doi: 10.1101/2021.11.09.466576
17. Centenera MM, Hickey TE, Jindal S, Ryan NK, Ravindranathan P, Mohammed H, et al. A Patient-Derived Explant (PDE) Model of Hormone-Dependent Cancer. Mol Oncol (2018) 12:1608–22. doi: 10.1016/j.molonc.2018.02.12354
18. Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, Mutuku SM, et al. Lipidomic Profiling of Clinical Prostate Cancer Reveals Targetable Alterations in Membrane Lipid Composition. Cancer Res (2021) 81:4981–93. doi: 10.1158/0008-5472.CAN-20-3863
19. Zhang W, Liao CY, Chiotau H, Incroci L, van Gent DC, van Weerden WM, et al. Apatulamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of non-Homologous End-Joining DNA Repair. Cancers (Basel) (2019) 11. doi: 10.3390/cancers11101593
20. Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex Vivo Culture of Human Prostate Tissue and Drug Development. Nat Rev Urol (2013) 10:483–7. doi: 10.1038/nrurol.2013.126
21. Shafi AA, Schiewer MJ, de Leeuw R, Dygliere E, McCue PA, Shah N, et al. Patient-Derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol (2018) 1:325–37. doi: 10.1016/j.euo.2018.04.019
22. Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, et al. Patient-Derived Models of Abiraterone- and Enzalutamide-Resistant Prostate Cancer Reveal Sensitivity to Ribosome-Directed Therapy. Eur Urol (2018) 74:562–72. doi: 10.1016/j.eururo.2018.06.020
23. Boissett C, Joncas FH, Park A, Berrehail Z, Pelletier JF, Gris T, et al. Using Ex Vivo Culture to Assess Dynamic Phenotype Changes in Human Prostate Macrophages Following Exposure to Therapeutic Drugs. Sci Rep (2021) 11:19299. doi: 10.1038/s41598-021-98903-y
24. Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, et al. ELOVL5 is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. Cancer Res (2021) 81:1704–18. doi: 10.1158/0008-5472.CAN-20-2511
25. Bray K, Chen HY, Karp CM, May M, Ganesan S, Karantza-Wadsworth V, et al. Bcl2 Modulation to Activate Apoptosis in Prostate Cancer. Mol Cancer Res (2009) 7:1487–96. doi: 10.1158/1541-7786.MCR-09-0166

AUTHOR CONTRIBUTIONS
LMP and LN jointly wrote and edited this manuscript. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported by Department of Defense Prostate Cancer Research Program Cancer Health Disparities Grant PC190699 (LN) and University of Illinois Cancer Center Cancer Biology Training Program Pilot Funding (LP).

ACKNOWLEDGMENTS
Figure 1 was created with Biorender.com.
26. Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual Roles of PARP-1 Promote Cancer Growth and Progression. *Cancer Discov* (2012) 2:1134–49. doi: 10.1158/2159-8290.CD-12-0120

27. Handle F, Pühr M, Schaef G, Lorito N, Hofer J, Gruber M, et al. The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models. *Mol Cancer Ther* (2018) 17:2722–31. doi: 10.1158/1535-7163.MCT-18-0508

28. Templeton AR, Jeffery PL, Thomas PB, Perera MPJ, Ng G, Calabrese AR, et al. Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management. *Front Oncol* (2021) 11:767697. doi: 10.3389/fonc.2021.767697

29. van de Merbel AF, van der Horst G, van der Pluijm G. Patient-Derived Tumour Models for Personalized Therapeutics in Urological Cancers. *Nat Rev Urol* (2021) 18:33–45. doi: 10.1038/s41566-020-00389-2

30. Johnson BP, Vitek RA, Geiger PG, Huang W, Jarrard DF, Lang JM, et al. Vital *Ex Vivo* Tissue Labeling and Pathology-Guided Micropunching to Characterize Cellular Heterogeneity in the Tissue Microenvironment. *Biotechniques* (2018) 64:13–9. doi: 10.2144/000114626

31. Tieu T, Irani S, Bremert KL, Ryan NK, Wojnilowicz M, Helm M, et al. Patient-Derived Prostate Cancer Explants: A Clinically Relevant Model to Assess Sirna-Based Nanomedicines. *Adv Healthc Mater* (2021) 10:e2001594. doi: 10.1002/adhm.202001594

32. Brady L, Kriner M, Coleman I, Morrissey C, Roadier M, True LD, et al. Inter- and Intra-Tumor Heterogeneity of Metastatic Prostate Cancer Determined by Digital Spatial Gene Expression Profiling. *Nat Commun* (2021) 12:1426. doi: 10.1038/s41467-021-21615-4

33. Pachynski RK, Kim EH, Miheeva N, Kotlov N, Ramachandran A, Postovalova E, et al. Single-Cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer. *Clin Cancer Res* (2021) 27:5478–90. doi: 10.1158/1078-0432.CCR-20-4217

34. Black S, Phillips D, Hickey JW, Kennedy-Darling J, Venkataraman VG, Samussik N, et al. CODEX Multiplexed Tissue Imaging With DNA-Conjugated Antibodies. *Nat Protoc* (2021) 16:3802–35. doi: 10.1038/s41596-021-00556-8

35. Figiel S, Pasqualin C, Bery F, Maupoil V, Vandier C, Potier-Cartereau M, et al. Functional Organotypic Cultures of Prostate Tissues: A Relevant Preclinical Model That Preserves Hypoxia Sensitivity and Calcium Signaling. *Am J Pathol* (2019) 189:1268–75. doi: 10.1016/j.ajpath.2019.02.017

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Perez and Nonn. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.